Which merger's better, Merck's or Pfizer's?

It's striking--bordering on shocking--how investors have reacted differently to the megamergers by Pfizer and Merck, Motley Fool says. Merck traded down right after the announcement, but investors have bid up the stock by 17 percent since Merck announced it would by Schering; conversely, Pfizer's shares are down 18.3 percent. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.